BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24561519)

  • 41. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
    Ravi D; Bhalla S; Gartenhaus RB; Crombie J; Kandela I; Sharma J; Mazar A; Evens AM
    Clin Cancer Res; 2014 Dec; 20(23):6023-33. PubMed ID: 25316819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
    Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dexamethasone-induced apoptosis and up-regulation of Bim is dependent on glycogen synthase kinase-3.
    Nuutinen U; Ropponen A; Suoranta S; Eeva J; Eray M; Pellinen R; Wahlfors J; Pelkonen J
    Leuk Res; 2009 Dec; 33(12):1714-7. PubMed ID: 19559478
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
    Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
    Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
    Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
    Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
    Ganai SA
    J Chemother; 2016 Aug; 28(4):247-54. PubMed ID: 27121910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
    Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
    J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.
    Dornetshuber-Fleiss R; Heilos D; Mohr T; Richter L; Süssmuth RD; Zlesak M; Novicky A; Heffeter P; Lemmens-Gruber R; Berger W
    Biochem Pharmacol; 2015 Feb; 93(3):318-331. PubMed ID: 25557295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway.
    Craxton A; Draves KE; Gruppi A; Clark EA
    J Exp Med; 2005 Nov; 202(10):1363-74. PubMed ID: 16301744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.
    Heffeter P; Atil B; Kryeziu K; Groza D; Koellensperger G; Körner W; Jungwirth U; Mohr T; Keppler BK; Berger W
    Eur J Cancer; 2013 Oct; 49(15):3366-75. PubMed ID: 23790465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
    Sajithlal GB; Hamed HA; Cruickshanks N; Booth L; Tavallai S; Syed J; Grant S; Poklepovic A; Dent P
    Mol Pharmacol; 2013 Oct; 84(4):562-71. PubMed ID: 23877009
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1231-40. PubMed ID: 23455452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
    Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
    Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.
    Shao YY; Chang YL; Huang CY; Hsu CH; Cheng AL
    Oncology; 2013; 85(5):312-6. PubMed ID: 24217400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
    Reynolds C; Roderick JE; LaBelle JL; Bird G; Mathieu R; Bodaar K; Colon D; Pyati U; Stevenson KE; Qi J; Harris M; Silverman LB; Sallan SE; Bradner JE; Neuberg DS; Look AT; Walensky LD; Kelliher MA; Gutierrez A
    Leukemia; 2014 Sep; 28(9):1819-27. PubMed ID: 24552990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.